The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

A compound that showed early promise in the treatment of Parkinson's disease in fruit flies has also shown neuroprotective ...

Brain implants, made from small clusters of brain cells, could help restore neural pathways damaged by Parkinson’s disease.

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

A Colorado Springs family hopes to win what they believe would be a landmark legal verdict by proving to jurors next month ...

Propranolol reduces Parkinson’s tremor and motor cortex activity, suggesting a new therapeutic approach beyond stress ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

ONAPGO is a prescription medicine used to treat motor fluctuations (OFF episodes) in adults with advanced Parkinson's disease (PD). It is not known if ONAPGO is safe and effective in children. Do not ...

A novel wireless photothermal DBS nanosystem uses nanoparticles to target and restore damaged neurons in Parkinson’s disease, ...

In a significant advancement for Parkinson’s Disease (PD) therapy, researchers have developed a targeted nano formulation ...